THE COMPANY.
AUSTRALIAN-US BIOTECH COMPANY NOVAPEP IS DEVELOPING NVP-202, AN AGONIST POLYPEPTIDE THAT MIMICS THE CELL SIGNALING ACTIVITY OF ACTIVATED PROTEIN C (APC).
Pioneers in APC & Peptide Mimetic Research.
The Founders behind Novapep’s
revolutionary Science.
Novapep’s co-founders, Profs John Griffin and Laurent Mosnier at The Scripps Research Institute in San Diego and Prof Chris Jackson at the University of Sydney, have conducted over 30 years of ground-breaking R&D in APC.
Prof Griffin and Prof Mosnier invented the PAR1 agonist peptide and Prof Mosnier developed the PAR3 agonist peptide. They subsequently developed NVP-202 - the PAR1/PAR3 conjugated bivalent agonist peptide, which is proven to reduce activation of the NLRP3 inflammasome.
NVP-202 Modifications.
Prof Akhter Hossain of The Florey Institute of Neuroscience and Mental Health is developing analogs of NVP-202 with significantly increased half-life, stability and bioavailability - the NVP-300 Series.
Prof Hossain's group has developed and published a cheaper and faster way to manufacture GLP-1 agonists with similar in vivo potency to semaglutide.